FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Machinaton	$D \subset$	20540	
Washington,	D.C.	20549	

Check this box if no longer subject to

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Instruction 1(b).		Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
-------------------	--	--

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

intende defense	es of the issue ed to satisfy the e conditions of ee Instruction 1	affirmative Rule 10b5-																
1		Reporting Person*  Master Fund,			2. Issuer Name <b>and</b> Ticker or Trading Symbol STANDARD BIOTOOLS INC. [ LAB ]					5. Relationship of Reporting Person(s) to Issue (Check all applicable)  Director  10% Owner			Owner					
(Last) 1350 AV SUITE 2		rst) (I THE AMERICA	Middle)		ate of E		Trans	actio	on (Mo	onth/Day/Year	)			Office below	er (give title v)	e	Other below	(specify )
(Street)				4. If	Amend	lment, [	Date o	f Ori	iginal	Filed (Month/l	Day/Yea		6. Indi Line)				•	Applicable
NEW YO	ORK NY	7 1	0019										<b>V</b>		filed by O filed by M on		•	
(City)	(Sta	ate) (2	Zip)															
		Table	I - Non-Deriva	ative	Secu	rities	Acq	uir	ed, [				cially	y Own	ed			
1. Title of S	Security (Inst	tr. 3)	2. Transaction Date (Month/Day/Ye	Execution Date, Tra		Tra Co	Transaction Disposed Of (D) (Ins					5. Amount of Securities Beneficially Owned Following		Form: Direct (D) or Indirect (I)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Со	de	v	Amount	(A) or (D)	Price		Transac	Reported Transaction(s) (Instr. 3 and 4)			
Common share	Stock, \$0.0	001 par value per	r 11/24/202	5			I	P		150,000	A	\$1.432	25(1)	64,20	00,000			See footnote <sup>(3)</sup>
Common share	Stock, \$0.0	001 par value per	r 11/25/202	5			I	P		7,550,000	A	\$1.303	31(2)	71,7:	50,000			See footnote <sup>(3)</sup>
Common share	Stock, \$0.0	001 par value per	r											2,90	01,062	Г	<b>)</b> <sup>(4)</sup>	
Common share	Stock, \$0.0	001 par value per	r											13,9	39,637			See footnote <sup>(5)</sup>
Common share	Stock, \$0.0	001 par value pe	r											2,74	4,219			See footnote <sup>(6)</sup>
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Trans Code 8)		5. Nur of Deriva Secur Acqui (A) or Dispo of (D) (Instr. and 5	ative rities ired sed	Exp	piratio	xercisable and n Date ay/Year)	Amo Secu Unde Deriv	cle and unt of irities erlying vative irity (Instr d 4)	De Se (In	Price of rivative curity estr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Dat Exe	te ercisat	Expiratio	n Title	Amoun or Numbe of Shares	r					
1		Reporting Person*  Master Fund																

Name and Address of Reporting Person*					
Casdin Partners Master Fund, L.P.					
		<del>,</del>			
(Last)	(First)	(Middle)			
1350 AVENUE (	OF THE AMER	ICAS			
SUITE 2600					
(Street)			_		
NEW YORK	NY	10019			
,					
(City)	(State)	(Zip)			
Name and Address of Reporting Person*					
Casdin Partners GP, LLC					

(Last)	(First)	(Middle)
SUITE 2600	F THE AMERICAS	
(Street) NEW YORK	NY	10019
(City)	(State)	(Zip)
1. Name and Address <u>Casdin Capita</u>	of Reporting Person*  1, LLC	
(Last) 1350 AVENUE O SUITE 2600	(First) OF THE AMERICAS	(Middle)
(Street) NEW YORK	NY	10019
(City)	(State)	(Zip)
1. Name and Address Casdin Eli	of Reporting Person*	
(Last) 1350 AVENUE O SUITE 2600	(First) OF THE AMERICAS	(Middle)
(Street) NEW YORK	NY	10019
CASDIN PRI	(State) s of Reporting Person* VATE GROWTH	(Zip) EQUITY
1. Name and Address CASDIN PRITEUND GP, LL (Last)	of Reporting Person*	
1. Name and Address CASDIN PRI FUND GP, LL  (Last) 1350 AVENUE O	s of Reporting Person* VATE GROWTH C  (First)  F THE AMERICAS	EQUITY
1. Name and Address CASDIN PRITEUND GP, LL  (Last) 1350 AVENUE CO SUITE 2600  (Street)	s of Reporting Person* VATE GROWTH C  (First)  F THE AMERICAS	EQUITY (Middle)
1. Name and Address CASDIN PRITEUND GP, LL  (Last) 1350 AVENUE OSUITE 2600  (Street) NEW YORK  (City) 1. Name and Address	s of Reporting Person* VATE GROWTH C  (First) OF THE AMERICAS  NY	EQUITY  (Middle)  10019  (Zip)
1. Name and Address CASDIN PRITEUND GP, LL  (Last) 1350 AVENUE OSUITE 2600  (Street) NEW YORK  (City) 1. Name and Address	s of Reporting Person* VATE GROWTH C  (First)  F THE AMERICAS  NY  (State)	EQUITY  (Middle)  10019  (Zip)
1. Name and Address CASDIN PRITEUND GP, LL  (Last) 1350 AVENUE OSUITE 2600  (Street) NEW YORK  (City) 1. Name and Address Casdin Private  (Last)	s of Reporting Person* VATE GROWTH C  (First) OF THE AMERICAS  NY  (State) s of Reporting Person* c Growth Equity I	EQUITY  (Middle)  10019  (Zip)  Fund II GP, LLC  (Middle)
1. Name and Address CASDIN PRITEUND GP, LL  (Last) 1350 AVENUE OSUITE 2600  (Street) NEW YORK  (City) 1. Name and Address Casdin Private  (Last)	of Reporting Person* VATE GROWTH CC  (First) OF THE AMERICAS  NY  (State) of Reporting Person* of Growth Equity I  (First) OF THE AMERICAS	EQUITY  (Middle)  10019  (Zip)  Fund II GP, LLC  (Middle)
1. Name and Address CASDIN PRITEUND GP, LL  (Last) 1350 AVENUE O SUITE 2600  (Street) NEW YORK  (City)  1. Name and Address Casdin Private  (Last) 1350 AVENUE O (Street)	of Reporting Person* VATE GROWTH CC  (First) OF THE AMERICAS  NY  (State) of Reporting Person* of Growth Equity I  (First) OF THE AMERICAS	EQUITY  (Middle)  10019  (Zip)  Fund II GP, LLC  (Middle)  SUITE 2600
1. Name and Address CASDIN PRITEUND GP, LL  (Last) 1350 AVENUE COSUITE 2600  (Street) NEW YORK  (City) 1. Name and Address Casdin Private  (Last) 1350 AVENUE COSUITE  (Street) NEW YORK  (City) 1. Name and Address (Street) NEW YORK	of Reporting Person* VATE GROWTH C  (First)  F THE AMERICAS  NY  (State)  F Growth Equity I  (First)  F THE AMERICAS	EQUITY  (Middle)  10019  (Zip)  Fund II GP, LLC  (Middle)  SUITE 2600  10019  (Zip)
1. Name and Address CASDIN PRITEUND GP, LL  (Last) 1350 AVENUE O SUITE 2600  (Street) NEW YORK  (City) 1. Name and Address Casdin Private  (Last) 1350 AVENUE O  (Street) NEW YORK  (City) 1. Name and Address Casdin Private  (Last) 1. Name and Address Casdin Private  (Last) 1. Name and Address Casdin Private  (Last)	of Reporting Person  VATE GROWTH  C  (First)  OF THE AMERICAS  NY  (State)  of Reporting Person  (First)  OF THE AMERICAS  NY  (State)  of Reporting Person  of Reporting Person  of Reporting Person	EQUITY  (Middle)  10019  (Zip)  Fund II GP, LLC  (Middle)  SUITE 2600  10019  (Zip)
1. Name and Address CASDIN PRITEUND GP, LL  (Last) 1350 AVENUE COSUITE 2600  (Street) NEW YORK  (City) 1. Name and Address Casdin Private  (Last) 1350 AVENUE COSTREE  (City) 1. Name and Address Casdin Private  (Last)	s of Reporting Person* VATE GROWTH C  (First)  F THE AMERICAS  NY  (State)  F THE AMERICAS  THE AMERICAS  S of Reporting Person*  F Growth Equity I  (First)  F THE AMERICAS	EQUITY  (Middle)  10019 (Zip)  Fund II GP, LLC (Middle) SUITE 2600  10019 (Zip)  Fund II, L.P.

Casdin Privat	e Growth Equity	Fund, L.P.
(Last)	(First)	(Middle)
1350 AVENUE	OF THE AMERICA	AS
SUITE 2600		
(Street)		
NEW YORK	NY	10019
-		
(City)	(State)	(Zip)

## **Explanation of Responses:**

- 1. The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of \$1.4290 to \$1.4396. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
- 2. The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of \$1.30 to \$1.3843. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
- 3. The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP.
- 4. The securities are owned directly by Eli Casdin.
- 5. The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin.
- 6. The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin.

## Remarks

Eli Casdin has been deputized to represent the Reporting Persons on the board of directors of the Issuer. By virtue of Mr. Casdin's representation, for purposes of Section 16 of the Securities Exchange Act of 1934 (the "Exchange Act"), each of the Reporting Persons may be deemed directors by deputization of the Issuer. Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Casdin Partners Master Fund, LP, By; Casdin Partners GP, LLC, its General Partner, By; /s/ Eli Casdin, Managing Member	11/26/2025
Casdin Partners GP LLC, By: /s/ Eli Casdin, Managing Member	11/26/2025
Casdin Capital LLC, By: /s/ Eli Casdin, Managing Member	11/26/2025
/s/ Eli Casdin, Eli Casdin	11/26/2025
Casdin Private Growth Equity Fund GP, LLC, By: /s/ Eli Casdin, Managing Member	11/26/2025
Casdin Private Growth Equity Fund GP II, LLC, By: /s/ Eli Casdin, Managing Member	11/26/2025
Casdin Private Growth Equity Fund, L.P., By: Casdin Private Growth Equity Fund GP, LLC, its General Partner, By: /s/ Eli Casdin, Managing Member	11/26/2025
Casdin Private Growth Equity Fund, L.P., By: Casdin Private Growth Equity Fund II GP, LLC, its General Partner, By: /s/ Eli Casdin, Managing Member	11/26/2025
** Signature of Reporting Person	Date

 $Reminder: Report \ on \ a \ separate \ line \ for \ each \ class \ of \ securities \ beneficially \ owned \ directly \ or \ indirectly.$ 

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.